article thumbnail

BCG-OPPI report: Winning in the Indian healthcare market to unlock disruptive growth

Express Pharma

India’s pharmaceutical market, currently valued at approximately $60 billion, is projected to double by 2030. The Indian healthcare sector is poised for rapid expansion, driven by a robust pharmaceutical ecosystem. Global pharmaceutical companies have played a pivotal role in transforming the healthcare sector in India.

article thumbnail

STAT+: Report: Tuberculosis R&D funding is up, but still short of goals and dominated by a few players

STAT

Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Just 9% came from the private sector, such as pharmaceutical companies. Meanwhile, the U.S. Continue to STAT+ to read the full story…

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Radiopharmaceuticals for prostate cancer to go nuclear with $6.3 bn in sales by 2030

Express Pharma

Radioligand therapies (RLTs) have received prominent attention from major pharmaceutical companies in treating prostate cancer. billion in sales by 2030, according to GlobalData. billion by 2030, far outshining Xofigo. billion by 2030. bn in sales by 2030 appeared first on Express Pharma.

article thumbnail

QMS market to value nearly $4b by 2030

European Pharmaceutical Review

According to the research, the pharmaceutical quality management systems market is projected to reach $3.97 billion by 2030. Some pharmaceutical companies are increasing their R&D spending to increase product numbers. Also noted in the report was the shift towards cloud-based systems.

article thumbnail

Formulation development outsourcing market to be worth over $60bn by 2030

European Pharmaceutical Review

billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 Pharmaceutical companies globally are significantly investing in R&D. percent between 2022 and 2030 (the forecast period) due to the growing demand for new drugs to tackle the high disease burden worldwide. percent from its 2022 value of $35.1

article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 The rising requirement for small-scale and encapsulated manufacturing processes necessary to assemble these products make it challenging for many pharmaceutical companies to alter their currently installed capacity.

Dosage 98
article thumbnail

The Benefits of Integrated CDMO Services: Streamlining Drug Development and Manufacturing

Drug Patent Watch

The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48 from 2023 to 2030. As a result, many companies are turning to integrated CDMOs to simplify their outsourcing processes and improve efficiency.